TORONTO, July 20 /CNW/ - Amorfix Life Sciences Ltd., a product development company focused on misfolded protein diseases, is holding a webcast conference call with Dr. Robert Gundel, President and CEO and James Parsons, Chief Financial Officer, to discuss 1) the recent agreement with Biogen Idec to develop antibody therapeutics for the treatment of ALS; 2) other recent business developments and 3) to review the company's near-term goals and objectives. This webcast follows a series of recent news releases describing Amorfix's business agreements and partnerships with a number of companies to advance Amorfix's growing pipeline of innovative products to treat a variety of misfolded protein diseases including ALS, Alzheimer's disease and cancer.
July 22, 2010, at 4:00 p.m. EST
Teleconference Dial-in Numbers:
Toronto participants: (647) 427-7450
North American participants toll-free: +1 (888) 231-8191
Passcode for all participants: 89359648
This teleconference will also be webcast at http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=3157000 and will be available for replay for 60 days.
Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing therapeutic products and diagnostic devices targeting misfolded protein diseases including ALS, cancer, and Alzheimer's disease. Amorfix utilizes its computational discovery platform, ProMIS(TM), to predict novel Disease Specific Epitopes ("DSE") on the molecular surface of misfolded proteins. Amorfix's lead therapeutic programs include antibodies and vaccines to DSEs in ALS, Alzheimer's disease and cancer. Amorfix's proprietary Epitope Protection(TM) (EP) technology enables it to specifically identify very low levels of aggregated misfolded proteins (AMP) in a sample. The Company's diagnostic programs include an ultrasensitive method for the detection of aggregated Beta-Amyloid in brain tissue and blood of animal models of Alzheimer's disease, months prior to observable amyloid formation, and human blood screening tests for Alzheimer's and early liver cancer detection. For more information about Amorfix, visit www.amorfix.com.
SOURCE Amorfix Life Sciences Ltd.
For further information: For further information: Dr. Robert Gundel, President & Chief Executive Officer, Amorfix Life Sciences Ltd., Tel: (416) 847-6957, Fax: (416) 847-6899, email@example.com; James Parsons, Chief Financial Officer, Amorfix Life Sciences Ltd., Tel: (416) 847-6929, Fax: (416) 847-6899, firstname.lastname@example.org